Discussions tagged “Adakveo”

Adakveo (crizanlizumab), recently approved for reducing vaso-occlusive crises (VOCs) in sickle cell patients 16+, is gaining traction. Unlike traditional analgesics, it targets VOCs at the source by preventing blood cells from sticking together. But is it right for everyone? How does it compare to existing treatments? Let's discuss side effects, efficacy, and personal experiences.